AtriCure, Inc. (ATRC) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. AtriCure, Inc. is a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The company operates as a single segment, developing and selling devices for cardiac tissue ablation, LAA exclusion, and peripheral nerve ablation globally.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Revenue | $134.3M | $115.9M | $394.0M | $341.0M |
| Gross Profit | $101.3M | $86.8M | $295.4M | $254.9M |
| Gross Margin | 75.5% | 74.9% | 75.0% | 74.7% |
| Operating Income (Loss) | $0.2M | ($7.4M) | ($11.9M) | ($25.5M) |
| Net Loss | ($0.3M) | ($7.9M) | ($13.2M) | ($29.1M) |
| Cash & Equivalents | $147.9M | $130.3M | $147.9M | $130.3M |
| Long-Term Debt | $61.9M | $61.9M | $61.9M | $61.9M |
| Operating Cash Flow (9M) | $37.3M | $6.4M | $37.3M | $6.4M |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenue increased 15.8% year-over-year (15.1% constant currency). YTD revenue grew 15.5%. Growth was driven by Appendage Management (+21.5% Q3) and Pain Management (+27.7% Q3).
- Profitability Improvement: The company achieved operating income of $0.2M in Q3 2025, a significant turnaround from an operating loss of $7.4M in Q3 2024. Net loss narrowed to $0.3M from $7.9M.
- Product Mix Shift: Minimally invasive ablation revenue declined 33.2% in Q3 2025 due to reduced Hybrid procedures as physicians adopt PFA catheters. This was offset by strong performance in open ablation and appendage management.
- Cash Flow: Operating cash flow for the nine months ended September 30, 2025, surged to $37.3M from $6.4M in the prior year, reflecting improved operating results and moderated inventory investment.
Guidance, Outlook, and Risks
- Recent Developments: The company launched the cryoICE cryoXT probe for pain management in Q3 2025. Enrollment for the LeAAPS clinical trial (6,500 patients) was completed in July 2025. The BoxX-NoAF trial began patient enrollment in October 2025.
- Capital Structure: In August 2025, the company executed a sale-and-leaseback transaction for its corporate headquarters, receiving $6.25M in proceeds and recording a financing obligation. The company maintains a $125M asset-backed revolving credit facility with $61.9M outstanding and $61.9M available capacity.
- Legal Contingencies: A lawsuit filed by former SentreHEART securityholders seeks up to $260M in damages regarding alleged failure to obtain PMA approval for the LARIAT System. Management intends to vigorously defend the claim; no liability has been recognized as the loss is not currently probable or estimable.
- Outlook: Management anticipates continued growth driven by product innovation and clinical science. No specific numerical guidance for the full year 2025 was provided in this filing.
Investor Verification Checklist
- Revenue Sustainability: Verify the durability of growth in Appendage Management and Pain Management given the decline in Minimally Invasive Ablation.
- Legal Exposure: Monitor the status of the SentreHEART litigation and any potential impact on contingent consideration or reputation.
- Clinical Trial Outcomes: Track the 5-year follow-up data from the LeAAPS trial and enrollment progress in the BoxX-NoAF trial.
- Debt Covenants: Confirm continued compliance with the fixed charge coverage ratio and minimum excess availability covenants under the ABL facility.
- Share-Based Compensation: Note the significant non-cash expense ($33.4M YTD) and its impact on future cash burn if operating margins compress.